MX1 and cancer: Although MX confers a significant benefit in progression-free and overall survival compared with other chemotherapeutic agents [13], only up to a 20% [14] response rate was found in metastatic breast cancer with MX treatment, suggesting that chemoresistance may be present in cancer cells.